Effects of antihypertensive treatment on cardiac IGF-1 during prevention of ventricular hypertrophy in the rat

Life Sci. 1999;64(18):1603-12. doi: 10.1016/s0024-3205(99)00097-1.

Abstract

There is some evidence that cardiac rather than circulating insulin-like growth factor-1 (IGF-1) levels contribute to the development of renovascular hypertensive left ventricular hypertrophy (LVH), remaining unknown the effects of antihypertensive drugs on IGF-1 levels. We have assessed here the preventive effects of enalapril, losartan, propanolol and alpha-methyldopa on left ventricle (LV) and circulating IGF-1 levels in a rat model of hypertension and LVH (Goldblatt, GB). Our results show that relative LV mass and the LV content of IGF-1 were significantly lower with all antihypertensive drugs in GB rats (p<0.001). Serum concentrations of IGF-1 were lower in GB rats treated with enalapril, alpha-methyldopa and propanolol (p<0.01), but not in those treated with losartan. These results support the hypothesis that local rather than seric IGF-1 contributes to the development of left ventricular hypertrophy induced by pressure overload in the rat.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects
  • Enalapril / pharmacology
  • Heart / drug effects*
  • Hypertrophy, Left Ventricular / prevention & control*
  • Insulin-Like Growth Factor I / metabolism*
  • Losartan / pharmacology
  • Male
  • Methyldopa / pharmacology
  • Myocardium / metabolism*
  • Propranolol / pharmacology
  • Radioimmunoassay
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antihypertensive Agents
  • Methyldopa
  • Insulin-Like Growth Factor I
  • Enalapril
  • Propranolol
  • Losartan